Share this article

The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Alpha-cinnamide compositions for cancer. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Alpha-cinnamide compositions for cancer is a key innovation area in immuno-oncology

Alpha-cinnamide-based compounds are largely modulators of epigenetic proteins such as histone deacetylases (HDACs). HDACs are enzymes that regulate epigenetics by the removal of acetyl groups from the lysine residues of proteins, such as histones. Histone deacetylases have been variously implicated in different disease settings, including cancer, neurodegeneration and inflammation, as well as autoimmune, infectious, metabolic, haematologic, and cardiovascular disorders. Broad-spectrum HDAC inhibitors have been approved for the treatment of cancer. The potential for HDAC inhibitors as treatment for non-oncology indications has been recognised, but, is yet to be approved.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of alpha-cinnamide compositions for cancer.

Key players in alpha-cinnamide compositions for cancer – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to alpha-cinnamide compositions for cancer

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Bristol-Myers Squibb 290 Unlock Company Profile
Vertex Pharmaceuticals 191 Unlock Company Profile
Gilead Sciences 145 Unlock Company Profile
Nippon Shinyaku 95 Unlock Company Profile
Pfizer 85 Unlock Company Profile
Karyopharm Therapeutics 68 Unlock Company Profile
Agios Pharmaceuticals 64 Unlock Company Profile
F. Hoffmann-La Roche 45 Unlock Company Profile
E. Merck 45 Unlock Company Profile
Wellstat Management Company 39 Unlock Company Profile
Biogen 39 Unlock Company Profile
Alembic Pharmaceuticals 38 Unlock Company Profile
Oryzon Genomics 35 Unlock Company Profile
AbbVie 34 Unlock Company Profile
Incyte 28 Unlock Company Profile
Takeda Pharmaceutical 27 Unlock Company Profile
Mallinckrodt 24 Unlock Company Profile
Revolution Medicines 23 Unlock Company Profile
Karolinska Development 23 Unlock Company Profile
ESSA Pharma 20 Unlock Company Profile
Bayer 20 Unlock Company Profile
Pulmokine 18 Unlock Company Profile
Galderma Research and Development 18 Unlock Company Profile
Jacobio Pharmaceuticals Group 17 Unlock Company Profile
Madrigal Pharmaceuticals 17 Unlock Company Profile
Active Biotech 17 Unlock Company Profile
Mitsubishi Chemical Group 17 Unlock Company Profile
Otsuka Holdings 17 Unlock Company Profile
Sanofi 16 Unlock Company Profile
Abbott Laboratories 14 Unlock Company Profile
Karus Therapeutics 14 Unlock Company Profile
Eli Lilly and 14 Unlock Company Profile
Imago BioSciences 13 Unlock Company Profile
Immunomet Therapeutics 13 Unlock Company Profile
Kirin Holdings 13 Unlock Company Profile
Alphabet 12 Unlock Company Profile
Cancer Research Technology 12 Unlock Company Profile
Nuvation Bio 11 Unlock Company Profile
MSD 11 Unlock Company Profile
Johnson & Johnson 10 Unlock Company Profile
Macrophage Pharma 10 Unlock Company Profile
Jiangsu Haosen Pharmaceutical Group 9 Unlock Company Profile
Fujian Haixi Pharmaceuticals 9 Unlock Company Profile
Perrigo 9 Unlock Company Profile
Shanghai Hansoh Biomedical 8 Unlock Company Profile
Merck & Co 8 Unlock Company Profile
Chroma Therapeutics 8 Unlock Company Profile
Sentinel Oncology 7 Unlock Company Profile
U.S. Department of Veterans Affairs 7 Unlock Company Profile
Basilea Pharmaceutica 7 Unlock Company Profile

Source: GlobalData Patent Analytics

Gilead Sciences is one of the key filers of patents in the alpha-cinnamide segment. It is engaged in the discovery, development, and commercialization of therapeutics  for the treatment of cardiovascular, haematological, respiratory inflammatory, and liver diseases, as well as cancer and human immunodeficiency virus (HIV) infection. In 2015, Gilead Sciences acquired EpiTherapeutics gaining a footprint in the area of epigenetic research and development.

In terms of application diversity, Otsuka Holdings is the top company, followed by Wellstat Management Company and Bayer. By geographic reach, Revolution Medicines holds the top position. Jacobio Pharmaceuticals Group and Mitsubishi Chemical Group are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.